NASDAQ · PLUR

Pluri Inc.

$1.64 -$0.14 (-7.87%) 1D Market open

Key Metrics

$19.21M
Market cap
P/E · TTM
$1.08M
Revenue · TTM
−$25.54M
Net income
EPS · TTM $-2.71
Dividend yield
Free cash flow −$21.69M
Beta · 1Y 1.12
EBITDA · TTM −$25.55M
Gross margin 43.0%

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Jul 13
    From its Feb 9 high, the share price fell 57%.

    Peak close $3.83 on Feb 9; trough close $1.63 on Jul 13. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -57%
  • May 21
    The stock moved -11.5% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, May 21
  • May 19
    The stock moved -19.2% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, May 19

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$19.21M
Enterprise value
Shares outstanding10.8M
52-wk range$1.56 – $5.68
Avg volume · 20D15.8K
Net cash
Book value / share$-1.97
IndustryBiological Products, (No Diagnostic Substances)
ExchangeNASDAQ
About Pluri Inc.
IPO dateOct 9, 1991
Employees142

Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunothera…

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S17.80
P/FCF
EV/EBITDA
EV/Sales
Graham №

Profitability

Gross 43.0%
Operating -2,410.8%
Net -2,366.9%
FCF -2,010.1%
ROE / ROIC 276.0% · —

Financial Health

Current ratio0.33
Quick ratio
Debt / equity
Debt / EBITDA
Net cash
Working capital−$21.54M

Cash Flow · TTM

Operating CF −$20.36M
Capex −$1.33M
Free cash flow −$21.69M
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

2 / 9
Weak fundamentals · 2 of 9 signals passing

Altman Z-Score

Insufficient balance-sheet inputs

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings